Novartis receives FDA approval for Rhapsido® , the only oral, targeted BTKi treatment for chronic spontaneous urticaria
Blue Jay Gold Corp. Announces Engagement of Oak Hill Financial Inc. for Investor Relations and Retention of Haywood Securities for Market Making Services
QIMC Highlights Technical Advisory Role on First Atlas Matane Natural Hydrogen Project Following Quebec Parliamentary Committee Appearance
